End-of-day quote
Shenzhen S.E.
06:00:00 2024-05-19 pm EDT
|
5-day change
|
1st Jan Change
|
19.9
CNY
|
+0.20%
|
|
-1.97%
|
-26.70%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
56,644
|
119,407
|
67,700
|
27,232
|
30,324
|
22,227
|
-
|
-
|
Enterprise Value (EV)
1 |
56,644
|
119,407
|
66,889
|
28,504
|
31,593
|
23,324
|
23,110
|
22,561
|
P/E ratio
|
97.5
x
|
173
x
|
54.1
x
|
-263
x
|
35.3
x
|
20.2
x
|
14
x
|
12.7
x
|
Yield
|
-
|
-
|
0.86%
|
-
|
0.74%
|
1.16%
|
2.36%
|
1.84%
|
Capitalization / Revenue
|
29.1
x
|
52.8
x
|
18.5
x
|
8.62
x
|
8.72
x
|
4.99
x
|
3.98
x
|
3.64
x
|
EV / Revenue
|
29.1
x
|
52.8
x
|
18.3
x
|
9.03
x
|
9.09
x
|
5.24
x
|
4.13
x
|
3.69
x
|
EV / EBITDA
|
76.3
x
|
135
x
|
35.5
x
|
-322
x
|
26.6
x
|
16.5
x
|
11.2
x
|
10.6
x
|
EV / FCF
|
475
x
|
-
|
-75.3
x
|
-37.3
x
|
100
x
|
73.7
x
|
26.5
x
|
14.7
x
|
FCF Yield
|
0.21%
|
-
|
-1.33%
|
-2.68%
|
1%
|
1.36%
|
3.78%
|
6.81%
|
Price to Book
|
20.6
x
|
16
x
|
7.82
x
|
4.17
x
|
3.36
x
|
2.16
x
|
1.77
x
|
1.8
x
|
Nbr of stocks (in thousands)
|
1,032,353
|
1,094,851
|
1,099,252
|
863,699
|
1,116,912
|
1,116,917
|
-
|
-
|
Reference price
2 |
54.87
|
109.1
|
61.59
|
31.53
|
27.15
|
19.90
|
19.90
|
19.90
|
Announcement Date
|
2/28/20
|
4/29/21
|
4/13/22
|
4/23/23
|
4/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,943
|
2,261
|
3,652
|
3,157
|
3,477
|
4,451
|
5,591
|
6,109
|
EBITDA
1 |
742.1
|
881.9
|
1,885
|
-88.53
|
1,190
|
1,416
|
2,058
|
2,126
|
EBIT
1 |
657.8
|
775.4
|
1,452
|
-317.6
|
948.9
|
1,218
|
1,789
|
1,889
|
Operating Margin
|
33.85%
|
34.29%
|
39.76%
|
-10.06%
|
27.29%
|
27.38%
|
31.99%
|
30.93%
|
Earnings before Tax (EBT)
1 |
663.4
|
772.4
|
1,439
|
-338.2
|
940.3
|
1,254
|
1,877
|
1,960
|
Net income
1 |
574.5
|
679.2
|
1,263
|
-132.7
|
861.3
|
1,069
|
1,548
|
1,680
|
Net margin
|
29.56%
|
30.04%
|
34.59%
|
-4.2%
|
24.77%
|
24.02%
|
27.68%
|
27.5%
|
EPS
2 |
0.5625
|
0.6312
|
1.138
|
-0.1200
|
0.7700
|
0.9857
|
1.423
|
1.566
|
Free Cash Flow
1 |
119.3
|
-
|
-888
|
-764.6
|
315.6
|
316.5
|
873.5
|
1,538
|
FCF margin
|
6.14%
|
-
|
-24.31%
|
-24.22%
|
9.08%
|
7.11%
|
15.62%
|
25.17%
|
FCF Conversion (EBITDA)
|
16.08%
|
-
|
-
|
-
|
26.53%
|
22.34%
|
42.45%
|
72.31%
|
FCF Conversion (Net income)
|
20.77%
|
-
|
-
|
-
|
36.64%
|
29.6%
|
56.44%
|
91.52%
|
Dividend per Share
2 |
-
|
-
|
0.5312
|
-
|
0.2000
|
0.2318
|
0.4687
|
0.3659
|
Announcement Date
|
2/28/20
|
4/29/21
|
4/13/22
|
4/23/23
|
4/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1,275
|
871.4
|
956.4
|
737.2
|
592.3
|
748.4
|
982.2
|
733.9
|
1,013
|
451.7
|
1,067
|
1,212
|
1,346
|
989.9
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
255.8
|
327.2
|
-239
|
64.69
|
-470.2
|
244.3
|
322
|
202.4
|
180.2
|
69.94
|
320.6
|
327.3
|
333.5
|
266.5
|
-
|
Operating Margin
|
20.07%
|
37.55%
|
-24.98%
|
8.77%
|
-79.37%
|
32.65%
|
32.78%
|
27.58%
|
17.79%
|
15.49%
|
30.04%
|
27%
|
24.77%
|
26.93%
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-
|
-
|
-153.1
|
82.64
|
-335.9
|
-
|
305
|
186.6
|
-
|
-
|
256.5
|
321.6
|
304.2
|
-
|
-
|
Net margin
|
-
|
-
|
-16.01%
|
11.21%
|
-56.7%
|
-
|
31.05%
|
25.43%
|
-
|
-
|
24.03%
|
26.53%
|
22.59%
|
-
|
-
|
EPS
2 |
0.2062
|
-
|
-0.2236
|
0.0693
|
-0.3600
|
-
|
0.2763
|
0.1600
|
-
|
-
|
0.2296
|
0.2879
|
0.2724
|
-
|
-
|
Dividend per Share
2 |
0.0531
|
-
|
-
|
-
|
-
|
-
|
0.1800
|
-
|
-
|
-
|
0.0838
|
0.0838
|
0.0838
|
0.1084
|
0.1084
|
Announcement Date
|
4/13/22
|
4/27/22
|
8/18/22
|
10/27/22
|
4/23/23
|
4/23/23
|
8/26/23
|
10/26/23
|
4/26/24
|
4/26/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
1,272
|
1,269
|
1,098
|
883
|
335
|
Net Cash position
1 |
-
|
-
|
811
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-14.37
x
|
1.067
x
|
0.775
x
|
0.4291
x
|
0.1574
x
|
Free Cash Flow
1 |
119
|
-
|
-888
|
-765
|
316
|
317
|
874
|
1,538
|
ROE (net income / shareholders' equity)
|
25.5%
|
12.6%
|
15.1%
|
-1.44%
|
9.26%
|
11.3%
|
12.7%
|
14.1%
|
ROA (Net income/ Total Assets)
|
15.8%
|
-
|
9.04%
|
-
|
-
|
7.45%
|
8.2%
|
10.1%
|
Assets
1 |
3,644
|
-
|
13,970
|
-
|
-
|
14,353
|
18,873
|
16,634
|
Book Value Per Share
2 |
2.670
|
6.810
|
7.870
|
7.560
|
8.090
|
9.210
|
11.20
|
11.10
|
Cash Flow per Share
2 |
0.4900
|
0.4000
|
1.500
|
0.4900
|
0.9300
|
0.7600
|
1.160
|
-
|
Capex
1 |
386
|
1,226
|
2,540
|
1,310
|
717
|
751
|
672
|
453
|
Capex / Sales
|
19.88%
|
54.2%
|
69.56%
|
41.5%
|
20.63%
|
16.87%
|
12.02%
|
7.42%
|
Announcement Date
|
2/28/20
|
4/29/21
|
4/13/22
|
4/23/23
|
4/26/24
|
-
|
-
|
-
|
Last Close Price
19.9
CNY Average target price
32.78
CNY Spread / Average Target +64.72% Consensus |
1st Jan change
|
Capi.
|
---|
| -26.70% | 3.07B | | -3.15% | 89.69B | | +3.95% | 41.34B | | -10.51% | 33.72B | | +58.49% | 26.11B | | -20.09% | 14.63B | | -8.92% | 12.84B | | -11.46% | 11.66B | | -43.05% | 11.52B | | +4.79% | 8.92B |
Biopharmaceuticals
|